David R. Liu Announced as Recipient of Agilent Thought Leader Award
Agilent Technologies Inc. has announced David R. Liu as the recipient of an Agilent Thought Leader Award.
Agilent Technologies Inc. (California, USA) has announced David R. Liu as the recipient of an Agilent Thought Leader Award. A prominent researcher in the field of genome editing, Dr. Liu is Professor and Director of the Merkin Institute of Transformative Technologies in Healthcare, Vice-Chair of the Faculty at the Broad Institute of MIT and Harvard, Professor of Natural Sciences and Professor of Chemistry and Chemical Biology at Harvard University, and a Howard Hughes Medical Institute Investigator.
“I’m humbled and excited that our lab has been chosen for this award—a reflection of the creativity and dedication of our students and postdocs,” said Dr. Liu. “We can’t wait to try some new lines of research catalyzed by Agilent’s generous gift as well as their capabilities.”
Dr. Liu’s work is focused on the use of molecular editing tools, such as CRISPR technology, and the development of base editing and prime editing to study and address genetic diseases, targeting the genetic mutations responsible for these disorders and “rewriting” them.
The Agilent Thought Leader Award programme promotes fundamental scientific advances by contributing financial support, products, and expertise to the research of influential thought leaders in the life sciences, diagnostics, and chemical analysis arenas. To learn more, visit the Agilent Thought Leader Award website at: https://www.agilent.com/univ_relation/TLP/index.shtml
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
